Abstract
Summary
A negative correlation of serum C-terminal telopeptide of type I collagen (telopeptide-C) was observed with bone mass density (BMD) in postmenopausal control (r = −0.70, p < 0.05) and osteoporotic females (r = −0.46, p < 0.05) indicating increased bone resorption in these subjects. Since telopeptide-C is a significant determinant of bone loss, it can be used, in combination with bone mass measurement, for the assessment of postmenopausal females.
Introduction
The aim of this study was to find out the significance of serum osteocalcin, a marker of bone formation, and C-terminal telopeptide of type I collagen, a marker of bone resorption, in evaluating osteoporotic patients and to find out their relationship with bone mass density.
Methods
One hundred and fifty (150) females; 50 premenopausal (age=31.13 ± 1.29), 50 postmenopausal (age = 54.36 ± 0.81) and 50 postmenopausal osteoporotic patients (age = 58.6 ± 0.701) were included in this study. The postmenopusal subjects, with and without osteoporosis, were selected from different osteoporotic clinics and healthy premenopausal females were selected from general population. Height, weight, BMI, waist/hip ratio, age at menarche, years since menopause in case of postmenopausal women, history of disease, and fracture, if any, were recorded. BMD assessment was done on calcaneous by peripheral ultrasound bone densitometery on Sahara Clinical Bone Sonometer and T-scores were calculated. Serum levels of osteocalcin and C-terminal telopeptide of type I collagen and calcium were measured.
Results
A lower BMD in postmenopausal subjects, with and without osteoporosis (p < 0.001), indicating increased bone loss with aging and menopause, was observed. A negative correlation was found between age and BMD (r = −0.67, p < 0.05). No correlation was found between osteocalcin and BMD among these groups, suggesting heterogeneity of osteocalcin fragments in serum that limits its significance in the evaluation of osteoporosis. A positive correlation was found between osteocalcin and telopeptide-C (r = 0.26, p < 0.05). A positive correlation of telopeptide-C with age (r = 0.45, p < 0.05) and a negative correlation with BMD (r = −0.46, p < 0.05) was observed indicating increased bone resorption in postmenopausal control and postmenopausal osteoporotic patients.
Conclusion
C-terminal telopeptide of type I collagen appears to be a significant determinant of bone loss and may be used as a valuable tool in the assessment of postmenopausal osteoporotic patients.
Similar content being viewed by others
References
Schousboe JT, Bauer DC, Nyman JA et al (2007) Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic woman at high risk of fracture for bisphosphonate therapy. Osteoporosis Int 18:201–210
Pongchaiyakul C, Kosulwat V, Charoenkiatkul S et al (2008) The association of dietary calcium, bone mineral density and biochemical bone turnover markers in rural Thai women. J Med Assoc Thai 91:295–302
Iki M, Akiba T, Matsumoto T et al (2004) Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 15:981–991
Looker AC, Bauer DC, Chesnut CH et al (2000) Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 11:467–480
Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767
Christopoulou GE, Stavropoulou A, Anastassopoulos G et al (2006) Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats. J Pharm Biomed Anal 41:891–897
Gundberg CM, Nishimoto SK (1999) Vitamin K dependent proteins of bone and cartilage. In: Seibel MJ, Robbins SP, Bilezikian JP (eds) Dynamics of bone and cartilage. Metabolism Academic, San Diego, pp 43–58
Ivaska KK, Pettersson K, Nenonen A et al (2005) Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 51:2362–2365
Seibel MJ (2003) Biochemical markers of bone remodeling. Endocrinol Metab Clin N Am 32:83–113
Trento LK, Pietropolli A, Ticconi C et al (2009) Role of type I collegen C telopeptide, bone specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women. J Obstet Gynacol Res 35:152–159
Lukaszkiewicz J, Karczmarewicz E, Pludowski P et al (2008) Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal woman: an EPOLOS study. Med Sci Monit 14:65–70
Gluer CC, Genant HK, Hans D et al (1997) Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement and current status. J Bone Miner Res. 12:1280–1282
Gerdhem P, Ivaska KK, Alatalo SL et al (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386–393
Ensurd KE, Palermo L, Black DM et al (1995) Hip and calcaneous bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res 10:1778–1787
Miller PD, Zapalowski C, Kulak CAM et al (1999) Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrin Metab 84:1867–1871
Pi YZ, Wu XP, Liu S et al (2006) Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women. J Bone Miner Metab 24:380–385
Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936
Majkic-Singh N, Iiic M, Ignjatovic S et al (2002) Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis. Clin Lab 48:407–413
Peichl P, Griesmacherb B, Marteau R et al (2001) Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers. Clin Biochem 34:131–139
Seibel MJ (2003) Biochemical markers of bone metabolism in the assessment of osteoporosis. Useful or not? J Endocrinol Invest 26:464–471
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lateef, M., Baig, M. & Azhar, A. Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females. Osteoporos Int 21, 751–755 (2010). https://doi.org/10.1007/s00198-009-1001-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-009-1001-3